Celonic AG Appoints Soenke Brunswieck as Vice President Cell & Gene Therapy
Basel, Switzerland, May 08, 2018 / B3C newswire / -- Celonic AG, the Swiss biologics contract development and manufacturing organization, has appointed Soenke Brunswieck as Vice President Cell & Gene Therapy to establish Celonic`s new portfolio of CDMO Services in Cell & Gene Therapy domain.
“Cell & Gene Therapy represents a new paradigm in human health, with the potential to resolve unmet medical needs to improve patients’ lives through effective and safe advanced therapeutic medicinal products (ATMPs)”, said Dr. Konstantin Matentzoglu, CEO at Celonic AG. "Celonic appointed Soenke specifically for his extensive expertise with platform technologies and manufacturing of Cell & Gene Therapy Products", added Dr. Matentzoglu.
Soenke is on-boarded by Celonic based on his excellent track record as Director of Business Development and Project Management at PharmaCell BV (now Lonza Netherlands BV), one of the leading CDMOs for Cell & Gene Therapies, based in the Netherlands. Prior to PharmaCell, Soenke was the Director of Marketing & Sales at CellGenix for over 10 years and was responsible for the creation and successful growth of the global market for GMP-reagents used in Cell and Gene Therapy.
Soenke Brunswieck, VP of Cell & Gene Therapy at Celonic added: „Celonic, as a premium quality-driven bio-pharmaceutical CDMO, now entering into the Cell & Gene Therapy services space, is taking a key strategic step to continue adding value to the fast-growing industry by developing and commercializing Cell Therapy & Gene Therapy Products“.
Celonic AG is a privately owned CDMO based in Basel, Switzerland, providing comprehensive process development and manufacturing services for New Biological Entities (NBEs), Biosimilars, and Cell Therapy & Gene associated services worldwide.
Celonic’s services include the development of cell lines, production processes, as well as the GMP and non-GMP manufacturing of biopharmaceutical drug substances and drug product. In addition, Celonic licenses its CHOvolution™ and GEX™ cell line technologies to clients, drug developers and service providers. The service portfolio is now extended to the manufacturing of gene vectors and allogenic cell batches. Applying empathy, efficiency and excellence, Celonic goes one step beyond expectations in all business aspects in order to help its clients attain their goals more efficiently and reliably.
About Soenke Brunswieck, Vice President Cell & Gene Therapy
Prior to joining Celonic, Soenke was working as Director Business Development & Project Management at PharmaCell BV (now Lonza Netherlands BV), one of the leading CMOs in Cell & Gene Therapy. From 2002 to 2013, he was working for CellGenix (Freiburg, Germany) as Director Marketing & Sales, where he was responsible the creation and successful growth of the market for GMP-reagents as used in cell therapy on a global basis. He also was working in several Marketing & Sales positions at Pharmacia & Upjohn, Glaxo Welcome and SmithKlineBeecham. Soenke studied Biology at the Technical University Munich and Max Planck Institute of Psychiatry. He obtained his PhD at the Klinikum Rechts der Isar in Munich.